# DKSH and Grünenthal Announce New Partnership Agreement to Accelerate Access to Innovative Pain Management Solutions Across Eight Markets in Asia-Pacific

- Link: https://www.thailand-business-news.com/pr-news/dksh-and-grunenthal-announce-new-partnership-agreement-to-accelerate-access-to-innovative-pain-management-solutions-across-eight-markets-in-asia-pacific
- Published: 2026-09-28T12:45:00+07:00
- Author: Media OutReach

#### _DKSH and Grünenthal have entered into a new regional partnership agreement covering eight Asia-Pacific markets. The collaboration combines Grünenthal’s leadership in pain management with DKSH Healthcare’s integrated end-to-end commercialization platform to accelerate access to innovative therapies and support future portfolio growth across the region._

 SINGAPORE – EQS Newswire – 28 September 2026 – DKSH Business Unit Healthcare, a
strategic healthcare business partner and leading provider of Market Expansion Services
for pharmaceutical, over-the-counter (OTC), consumer health and medical device companies,
has expanded its partnership with Grünenthal, a global leader in pain management
and research. Under the new regional agreement, DKSH will support the commercialization
of four products from Grünenthal’s specialty pain portfolio, including the launch
of Qutenza®, Vimovo®, Palexia® and Zomig® in up to eight markets in Asia-Pacific,
namely Hong Kong, Indonesia, Malaysia, Philippines, Singapore, Taiwan, Thailand,
and Vietnam. The agreement marks the next phase of a successful partnership which
previously covered three medicines from Grünenthal’s established portfolio, strengthening
the commitment of both companies to improving access to holistic pain management
solutions for patients across the region.

 Grünenthal has built a leading position in pain management globally and is expanding
the reach of its innovative portfolio across Asia-Pacific. Through this partnership
expansion, DKSH Healthcare can further leverage its integrated capabilities spanning
regulatory affairs, market access, medical affairs, patient solutions, commercial
excellence, omnichannel engagement, distribution, and supply chain management to
successfully launch new therapies, unlock sustainable growth and deliver long-term
portfolio expansion across the region.

 The collaboration is designed around DKSH Healthcare’s regional partnership model,
which enables coordinated execution across multiple markets while maintaining strong
local market focus. Supported by integrated governance, launch excellence capabilities,
cross-functional expertise, and performance management framework – the alliance 
is designed to accelerate access to innovative pain therapies while supporting healthcare
professionals in addressing unmet medical needs.

 “Qutenza, Vimovo, Palexia, and Zomig have delivered meaningful benefits to millions
of people living with pain worldwide. Through our partnership with DKSH, we are 
taking another significant step toward broadening access to proven therapies and
extending the reach of our medicines to more patients who need them,” said Jan Adams,
Chief Commercial Officer, Grünenthal. “With pain affecting potentially hundreds 
of millions across Asia-Pacific, new care options that meet the broad spectrum of
patient needs are critical. We are proud to join forces with DKSH to help improve
lives and advance our vision of a World Free of Pain.”

 “This partnership marks another important milestone in DKSH Healthcare’s new chapter
of growth. Grünenthal is a globally recognized leader in pain management, and we
are proud to further strengthen our relationship through an expanded alliance partnership
spanning up to eight markets across Asia-Pacific. Leveraging our regional partnership
model and integrated end-to-end commercialization platform, we are well positioned
to accelerate growth, improve access to innovative therapies for patients across
the region, and advance our mission of delivering Healthcare for All,” said Patrik
Grande, Global Head of Business Unit Healthcare, DKSH.

The issuer is solely responsible for the content of this announcement.

#### About DKSH

For more than 160 years, DKSH has been delivering growth for companies in Asia Pacific,
Europe, and North America across its Business Units Healthcare, Consumer Goods, 
Performance Materials, and Technology. As a leading Market Expansion Services provider,
DKSH offers sourcing, market insights, marketing and sales, e-commerce, distribution
and logistics as well as after-sales services, following its purpose of enriching
people’s lives. DKSH is a participant of the United Nations Global Compact and adheres
to its principles-based approach to responsible business. Listed on the SIX Swiss
Exchange, DKSH operates in 35 markets with 26,840 specialists, generating net sales
of CHF 11.1 billion in 2025. DKSH Business Unit Healthcare distributes pharmaceuticals,
consumer health, over-the-counter products and medical devices. With around 7,580
specialists, the Business Unit generated net sales of CHF 5.8 billion in 2025. [www.dksh.com/hec](http://www.dksh.com/hec)

![](//track.media-outreach.com/index.php/WebView/490626/36955)

**Source** : [DKSH and Grünenthal Announce New Partnership Agreement to Accelerate Access to Innovative Pain Management Solutions Across Eight Markets in Asia-Pacific](https://www.media-outreach.com/news/switzerland/2026/09/28/490626/?rand=186006)

---

  |  This article was produced by Media OutReach, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not reflect the opinions of Thailand Business News. |

---

![Media OutReach Newswire](https://i0.wp.com/www.thailand-business-news.com/wp-content/
uploads/2025/04/media-outreach-20025.png?ssl=1)
